2030 Safety Side effects 
Pharmaceutical Technology
DECEMBER 16, 2022
The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.
European Pharmaceutical Review
OCTOBER 12, 2022
The safety data from the trial was consistent with earlier trial data. This is promising when side effects such as ARIAs are often detected in magnetic resonance imaging brain scans of patients who are given the antibodies. If the drug is approved, GlobalData estimates that global sales for HMTM will reach $127 million by 2030.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 7, 2022
On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.
European Pharmaceutical Review
MARCH 24, 2023
Pegozafermin also has a favourable safety and tolerability profile, with few gastrointestinal (GI) side effects. In the European Union, NASH affects nearly 10 million people and is expected to increase by more than 40 percent by 2030. It is becoming the leading cause for liver transplants.
PM360
AUGUST 9, 2022
billion in 2030 at a CAGR of 9.2%. This allows patients to complete the whole treatment process, from drug preparation and drug administration to treatment monitoring, side effect reporting, and communication, with one click on their device and smartphone. from 2021 and reach $4.2 billion in 2025.
pharmaphorum
SEPTEMBER 30, 2022
. “What we cannot know yet is whether that effect increases over time in an individual. Another key factor to consider is the safety profile of the drug, particularly with regard to amyloid-related imaging abnormalities (ARIA) that are always a risk with amyloid-targeting drugs, causing oedema (ARIA-E) and haemorrhages (ARIA-H).
Celeritas
SEPTEMBER 26, 2022
The QR code payment market is projected to rise to $35 billion by 2030. Safety and Security: Geriatricians and Pediatricians mainly manage patients who are either too old or too young to take care of themselves. Now hospitals and elderly homes can ensure the safety of their charges. B) Aiding Healthcare Recipients: .
Expert insights. Personalized for you.
59 
Let's personalize your content